ORION -B- (OFK BE) stock market data APIs
€63.3869
0(0%)
as of July 1, 2025
Try our APIs with
free plan!
ORION -B- Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for OFK.BE.
Prev. Close
63.3869
Open
63.3869
High
63.3869
Low
63.3869
52 wk Range
38.3049-65.1
Market Cap
4 882 M
EPS
1.32
Dividends (Yield)
0.0443
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ORION -B- data using free add-ons & libraries
Get ORION -B- Fundamental Data
ORION -B- Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2018-06-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ORION -B- News
New
141,959 Orion Corporation A shares converted into B shares
Orion Oyj ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 23 June 2025 at 9.30 EEST 141,959 Orion Corporation A shares converted i...
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer
Orion Oyj ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion fo...
Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs
Orion Oyj ORION CORPORATION PRESS RELEASE 17 JUNE 2025 at 9.00 EEST Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-ge...
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer
Orion Oyj ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer Darolutamide is the first and o...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
